Stockscreener 앱 받기
16.70
7.32%
-1.2966
전일 마감가:
$18.00
열려 있는:
$17.98
하루 거래량:
636.32K
Relative Volume:
0.49
시가총액:
$1.38B
수익:
$46.02M
순이익/손실:
$-70.80M
주가수익비율:
-9.1777
EPS:
-1.82
순현금흐름:
$-1.61M
1주 성능:
-6.59%
1개월 성능:
+31.05%
6개월 성능:
+19.07%
1년 성능:
+153.53%
1일 변동 폭
$16.41
$17.98
1주일 범위
$16.41
$18.87
52주 변동 폭
$3.91
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
명칭
Eyepoint Inc
전화
617-926-5000
주소
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
16.65 | 1.49B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.45 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
769.77 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
729.48 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.27 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.56 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-22 | 개시 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Mizuho | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2021-01-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-06 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 재개 | Laidlaw | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
모두보기
Eyepoint Inc 주식(EYPT)의 최신 뉴스
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $30.00 - MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright raises EyePoint stock price target to $30 on DME trial progress - Investing.com
Chardan Raises Price Target on EyePoint Pharmaceuticals to $29 From $27, Keeps Buy Rating - marketscreener.com
EyePoint (EYPT) Analyst Rating Update: Price Target Increased to $30 | EYPT Stock News - GuruFocus
EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check (NASDAQ:EYPT) - Seeking Alpha
EyePoint (EYPT) Q4 2025 Earnings Call Transcript - The Globe and Mail
Earnings Summary: EyePoint (EYPT) Q4 2025 net loss widens - AlphaStreet News
Is It Too Late To Consider EyePoint (EYPT) After A 1‑Year Surge And DCF Upside? - simplywall.st
EyePoint: Fourth Quarter Financial Results Overview - Bitget
EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising Clinical Advances - GuruFocus
Chardan raises EyePoint stock price target to $29 on cash position - Investing.com UK
EYPT (EyePoint) Equity-to-Asset : 0.80 (As of Sep. 2025) - GuruFocus
EYPT (EyePoint) ROE % : -107.10% (As of Sep. 2025) - GuruFocus
Chardan Capital Issues Positive Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price - MarketBeat
Chardan Capital Raises Price Target for EYPT to $29.00, Maintains Buy Rating | EYPT Stock News - GuruFocus
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 4.7%Should You Sell? - MarketBeat
Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop - Investing.com South Africa
EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Eyepoint Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
EYPT: DURAVYU's pivotal Phase III trials progress with strong safety, efficacy, and funding into 2027 - TradingView
EYPT: DURAVYU advanced in pivotal trials with strong cash reserves and key data readouts ahead - TradingView
EyePoint Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eyepoint Pharma earnings missed by $0.06, revenue fell short of estimates - Investing.com Canada
EyePoint, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
EyePoint Inc (NASDAQ:EYPT) Stock Falls on Q4 Earnings and Revenue Miss - ChartMill
EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates - Nasdaq
EyePoint Pharmaceuticals' Q4 Net Loss Widens, Revenue Drops - marketscreener.com
Earnings Flash (EYPT) EyePoint Posts Q4 Net Loss $0.81 a Share, vs. FactSet Est of $0.77 Loss - marketscreener.com
Earnings Flash (EYPT) EyePoint, Inc. Reports Q4 Revenue $620,000, vs. FactSet Est of $990,000 - marketscreener.com
EYPT Forecasts Financial Stability Through Key Program Milestones - GuruFocus
EYEPOINT PHARMACEUTICALS ($EYPT) Releases Q4 2025 Earnings - Quiver Quantitative
EyePoint: Q4 Earnings Snapshot - marketscreener.com
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments - TradingView
EyePoint Pharmaceuticals Q4 revenue plunges, net loss widens - TradingView
EYPT: DURAVYU Phase 3 trials progress, with strong cash reserves funding operations into Q4 2027 - TradingView
EyePoint (Nasdaq: EYPT) deepens 2025 loss while pushing DURAVYU into Phase 3 - Stock Titan
Earnings Summary: EyePoint Q4 - Benzinga
EyePoint at TD Cowen Conference: DURAVYU’s Market Potential By Investing.com - Investing.com Canada
EYPT: Phase 3 trials advance with unique IL-6 mechanism, targeting a $15B global retina market - TradingView
A Preview Of EyePoint Pharmaceuticals's Earnings - Benzinga
EyePoint Pharmaceuticals to Announce Q4 Earnings on March 4 - Intellectia AI
Eyepoint Pharma earnings up next as pivotal trial data looms By Investing.com - Investing.com Canada
Eyepoint Pharma earnings up next as pivotal trial data looms - Investing.com Nigeria
EyePoint Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Performance Metrics - Markets Mojo
EyePoint begins dosing in phase 3 DME trials for DURAVYU - Eyes On Eyecare
EYPT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
EyePoint doses first patients in phase 3 DME trials for DURAVYU - Investing.com Australia
Eyepoint Inc topline data for Duravyu in dme anticipated in 2h 2027 - marketscreener.com
Eyepoint Inc Topline Data For Duravyu In Dme Anticipated In 2H 2027 - TradingView
EyePoint Doses First Patients in Phase 3 Trials of Duravyu in Diabetic Macular Edema - marketscreener.com
Eyepoint Inc (EYPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.50%
자본화:
|
볼륨(24시간):